Traded Value
Buffett's senior apprenticeSince the assistance is mutually beneficial, why is one rising while the other is still in a half-dead state? Can any expert explain this?
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Omeros' stock surged 181% to $11.52 after a $340 million deal with Novo Nordisk for exclusive rights to develop zaltenibart. Despite this, Omeros faces challenges, including a history of losses and uncertain FDA approval for its lead candidate, narsoplimab. While the deal provides a cash boost, the company's future hinges on zaltenibart's success in trials, making it a high-risk investment. Investors with low risk tolerance may want to monitor rather than invest in Omeros.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
